Sagimet Biosciences (SGMT) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

SGMT Sagimet Biosciences

Watchlist

4.500
-0.020-0.44%

Close Nov 21 16:00 ET

4.500
0.0000.00%

Post 16:00 ET

144.88MMarket Cap-3862P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Sagimet Biosciences Insider Stock Sellers Must Be Relieved As Market Cap Falls To US$141m
Simply Wall StNov 20 06:37 ET
Sagimet Biosciences Presents Clinical Denifanstat And Preclinical FASN Inhibitor Data At AASLD The Liver Meeting 2024
BenzingaNov 18 08:01 ET
Institutional Investors in Sagimet Biosciences Inc. (NASDAQ:SGMT) See US$36m Decrease in Market Cap Last Week, Although Long-term Gains Have Benefitted Them.
Yahoo FinanceNov 18 05:15 ET
Sagimet Biosciences Advances MASH Treatment With Denifanstat
TipRanksNov 14 23:34 ET
Sagimet Biosciences, Inc.: Strategic Advancements and Financial Robustness Drive Buy Rating
TipRanksNov 14 21:15 ET · Ratings
Sagimet Biosciences Reports Q3 EPS (45c) Vs (35c) Last Year
TipRanksNov 14 08:09 ET

Comments

Jaguar8

Nov 18 09:47

NEWS PM

$Sagimet Biosciences (SGMT.US)$
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
Sagimet Biosciences presented Phase 2b data for denifanstat, its fatty acid synthase (FASN) inhibitor, at AASLD 2024. The FASCINATE-2 trial showed significant improvement in liver fibrosis in high-risk MASH patients, particularly in the F3 population where 49% of denifanstat-treated patients showed improvement versus 13% for placebo. AI-ba...

Jaguar8

Nov 12 05:31

NEWS

$Sagimet Biosciences (SGMT.US)$
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
Ascletis Pharma has completed enrollment of 480 patients in its Phase III clinical trial of ASC40 (denifanstat), a once-daily oral tablet for treating moderate to severe acne. The randomized, double-blind, placebo-controlled trial began on January 24, 2024, with patients divided equally between treatment and placebo groups. The study will evalua...

Trytosaveabit

Oct 29 06:04

Update

$Sagimet Biosciences (SGMT.US)$ Reuters· 3 mins ago
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions With FDA on the Development of Denifanstat for Mash; Phase 3 Program Initiation Expected by End of 2024

Jaguar8

Oct 11 06:04

NEWS

$Sagimet Biosciences (SGMT.US)$
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
Sagimet Biosciences Inc. (Nasdaq: SGMT) announced the publication of results from their Phase 2b FASCINATE-2 clinical trial of denifanstat in The Lancet Gastroenterology & Hepatology. The trial, conducted on patients with biopsy-confirmed metabolic-dysfunction associated steatohep...